Related Experiment Video
Updated: Mar 19, 2026
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing
Marieke Hylebos1, Guy Van Camp2, Jan P van Meerbeeck3
1Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium; Center for Oncological Research, University of Antwerp, Antwerp, Belgium.
Abstract:
Malignant pleural mesothelioma (MPM) is a rare yet aggressive tumor that is causally associated with-mostly professional-asbestos exposure. Given the long latency between exposure and disease, and because asbestos is still being used, MPM will remain a global health issue for decades to come. Notwithstanding the increasing incidence of MPM and the fact that patients with MPM face a poor prognosis, currently available treatment options are limited. To enable the development of novel targeted therapies, identification of the genetic alterations underlying MPM will be crucial. The first studies reporting on the genomic background of MPM identified recurrent somatic mutations in a number of tumor suppressor genes (i.e., cyclin-dependent kinase inhibitor 2A gene [CDKN2A], neurofibromin 2 (merlin) gene [NF2], and BRCA1 associated protein 1 gene [BAP1]). More recently, massively parallel sequencing strategies have been used and have provided a more genome-wide view on the genetic landscape of MPM. This review summarizes their results, describing alterations that cluster mainly in four pathways: the tumor protein p53/DNA repair, cell cycle, mitogen-activated protein kinase, and phosphoinisitide 3-kinase (PI3K)/AKT pathways. As these pathways are important during tumor development, they provide interesting candidates for targeting with novel drugs.
Insights
Malignant pleural mesothelioma (MPM) is a rare cancer linked to asbestos. Identifying genetic changes in key pathways like cell cycle and DNA repair is crucial for developing new targeted therapies.
Area of Science:
- Oncology
- Genetics
- Environmental Health
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive cancer primarily caused by asbestos exposure.
- Despite increasing incidence and poor prognosis, effective treatments for MPM remain limited.
- Asbestos use continues, making MPM a persistent global health concern.
Purpose of the Study:
- To review the current understanding of the genetic alterations underlying MPM.
- To identify key molecular pathways involved in MPM development.
- To highlight potential targets for novel therapeutic strategies.
Main Methods:
- Summary of findings from genomic studies on MPM.
- Analysis of recurrent somatic mutations in tumor suppressor genes (e.g., CDKN2A, NF2, BAP1).
- Integration of results from massively parallel sequencing to provide a genome-wide view.
Main Results:
- MPM genetic alterations predominantly affect four key pathways: tumor protein p53/DNA repair, cell cycle, mitogen-activated protein kinase (MAPK), and phosphoinositide 3-kinase (PI3K)/AKT.
- Recurrent mutations identified in critical tumor suppressor genes.
- Genomic landscape analysis reveals common dysregulated pathways.
Conclusions:
- Understanding the genetic landscape of MPM is essential for developing targeted therapies.
- The identified pathways represent promising targets for novel drug development in MPM treatment.
- Further research into these genetic alterations could significantly improve patient outcomes.
